#1 Clinical Trials Search in Europe

Fulvestrant

Fulvestrant, also known by its brand name Faslodex, is an important drug being studied in clinical trials for the treatment of breast cancer. This article explores how fulvestrant is being investigated as a potential therapy option, particularly for postmenopausal women with hormone receptor-positive breast cancer. We’ll look at key trials examining fulvestrant’s efficacy, safety, and potential benefits compared to other treatments.

Table of Contents

What is Fulvestrant?

Fulvestrant is a medication used in the treatment of certain types of breast cancer. It is also known by its brand names Faslodex and Faslodex® [1][2]. This drug is specifically designed for postmenopausal women with hormone receptor-positive breast cancer that has advanced or spread to other parts of the body (metastatic breast cancer) [2].

How Fulvestrant Works

Fulvestrant belongs to a class of drugs called estrogen receptor antagonists. It works by blocking the effects of estrogen on cancer cells. Estrogen can stimulate the growth of certain breast cancers, and by blocking its action, Fulvestrant helps to slow down or stop the growth of these cancer cells [3].

Conditions Treated with Fulvestrant

Fulvestrant is primarily used to treat:

  • Advanced breast cancer: This refers to cancer that has spread beyond the breast to nearby tissues or lymph nodes.
  • Metastatic breast cancer: This is when the cancer has spread to distant parts of the body, such as the bones, lungs, brain, or liver.
  • Hormone receptor-positive breast cancer: This type of breast cancer has cells with receptors for either estrogen (ER-positive) or progesterone (PR-positive), or both [2].

It’s important to note that Fulvestrant is typically used in patients whose cancer has progressed after previous endocrine (hormonal) therapy [3].

How Fulvestrant is Administered

Fulvestrant is given as an intramuscular injection, typically into the buttocks. The usual dose is 500 mg, which is often administered as two 250 mg injections, one in each buttock. The treatment schedule usually involves:

  • Initial doses on days 1, 15, and 29 of the first month
  • Subsequent doses once every 28 days thereafter [2]

This method of administration allows for a steady release of the medication into your body over time.

Efficacy of Fulvestrant

Clinical trials have shown that Fulvestrant can be effective in treating hormone receptor-positive advanced or metastatic breast cancer. Some key findings include:

  • Progression-Free Survival (PFS): This is the length of time during and after treatment that a patient lives with the disease but it does not get worse. Studies have shown that Fulvestrant can improve PFS compared to some other treatments [2].
  • Overall Survival (OS): This refers to how long a patient lives after starting treatment. Some studies have indicated that Fulvestrant may improve overall survival in certain patient groups [2].
  • Objective Response Rate (ORR): This is the proportion of patients whose cancer shrinks or disappears after treatment. Fulvestrant has shown promising results in terms of ORR in various studies [3].

Potential Side Effects

Like all medications, Fulvestrant can cause side effects. Common side effects may include:

  • Injection site pain or discomfort
  • Nausea
  • Fatigue
  • Hot flashes
  • Joint pain

It’s important to discuss any side effects you experience with your healthcare provider [4].

Fulvestrant in Combination Therapies

Researchers are exploring the use of Fulvestrant in combination with other cancer treatments to potentially improve outcomes. Some combinations being studied include:

  • Fulvestrant with Palbociclib: This combination is being studied for patients whose disease has progressed after prior endocrine therapy [4].
  • Fulvestrant with Gedatolisib: This combination is being investigated for its potential to improve treatment outcomes [5].
  • Fulvestrant with PF-07220060: This is another combination being studied for advanced or metastatic breast cancer [6].

Impact on Quality of Life

Researchers are not only interested in how Fulvestrant affects cancer progression, but also how it impacts patients’ quality of life. Studies have used various questionnaires to assess aspects such as:

  • Physical well-being
  • Emotional well-being
  • Social functioning
  • Breast cancer-specific concerns

These assessments help to understand how the treatment affects patients’ overall health and daily life beyond just controlling the cancer [2].

Aspect Details
Primary Use Treatment of hormone receptor-positive breast cancer in postmenopausal women
Administration Intramuscular injection, typically 500 mg
Dosing Schedule Days 1, 15, 29 for first month, then monthly
Mechanism of Action Blocks and degrades estrogen receptors in cancer cells
Key Clinical Trials Comparing fulvestrant to aromatase inhibitors, evaluating as maintenance therapy
Outcome Measures Progression-free survival, overall survival, objective response rate, clinical benefit rate
Potential Benefits May be as effective or more effective than some other hormone therapies for certain patients
Common Side Effects Injection site pain, nausea, bone pain, headache, hot flashes
Ongoing Research Evaluating efficacy in different treatment settings, combinations with other therapies

FAQ

  • What is fulvestrant and how does it work? Fulvestrant is a type of hormone therapy used to treat breast cancer. It works by blocking and degrading estrogen receptors in cancer cells, which can help slow or stop the growth of hormone receptor-positive breast tumors.
  • What types of breast cancer is fulvestrant used to treat? Fulvestrant is primarily used to treat hormone receptor-positive (ER-positive and/or PR-positive) breast cancer in postmenopausal women. It is often used for advanced or metastatic breast cancer that has progressed after treatment with other hormone therapies.
  • How is fulvestrant administered? Fulvestrant is given as an intramuscular injection, typically 500 mg, into the buttocks. The usual schedule is on days 1, 15, and 29 for the first month, then once monthly thereafter.
  • What are some potential side effects of fulvestrant? Common side effects may include injection site pain, nausea, bone pain, headache, and hot flashes. More serious but less common side effects can include liver problems and blood clots. Your doctor will monitor you for side effects during treatment.
  • How does fulvestrant compare to other hormone therapies for breast cancer? Clinical trials are comparing fulvestrant to other treatments like aromatase inhibitors. Some studies suggest fulvestrant may be as effective or potentially more effective than certain other hormone therapies for some patients, with a different side effect profile. However, more research is needed to fully understand how it compares.

Ongoing Clinical Trials on Fulvestrant

  • A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain

  • Study of inavolisib and fulvestrant for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of MK-5684 compared to standard therapy in patients with breast cancer, ovarian cancer, or endometrial cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +3

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Norway

  • Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Bulgaria Czechia France Germany Hungary +4

Glossary

  • Fulvestrant: A type of hormone therapy drug used to treat breast cancer. It works by blocking and degrading estrogen receptors in cancer cells.
  • Hormone receptor-positive breast cancer: Breast cancer cells that have receptors for estrogen (ER-positive) and/or progesterone (PR-positive). These cancers may be treated with hormone therapies.
  • Metastatic breast cancer: Breast cancer that has spread beyond the breast to other parts of the body, such as the bones, liver, or lungs.
  • Aromatase inhibitor: A class of drugs that lower estrogen levels in postmenopausal women by blocking the enzyme aromatase, which is involved in estrogen production.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Clinical benefit rate (CBR): The percentage of patients who have a complete response, partial response, or stable disease for a certain period of time.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Bioequivalence: The property of two drug products having the same biological effect in the body.

References

  1. https://clinicaltrials.gov/study/NCT02795039
  2. https://clinicaltrials.gov/study/NCT01602380
  3. https://clinicaltrials.gov/study/NCT00305448
  4. https://clinicaltrials.gov/study/NCT01942135
  5. https://clinicaltrials.gov/study/NCT02684032
  6. https://clinicaltrials.eu/trial/study-of-pf-07220060-and-fulvestrant-for-adults-with-advanced-or-metastatic-hr-positive-her2-negative-breast-cancer-after-previous-treatment/